Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the first line treatment of postmenopausal women with hormone positive metastatic or locally advanced breast cancer

Next Previous
X
Search
Trial Profile

A pilot open-label, phase II, single-arm study to evaluate the association of biomarkers of hormonal resistance and the mTOR pathway with the clinical efficacy of everolimus plus letrozole in the first line treatment of postmenopausal women with hormone positive metastatic or locally advanced breast cancer

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 26 Aug 2014

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Everolimus (Primary) ; Letrozole (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Sponsors Novartis

    • Most Recent Events

    • 11 Aug 2014 Status changed from recruiting to discontinued as reported by European Clinical Trials Database record.
    • 03 Mar 2014 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top